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ABSTRACT
Background:  Apoptosis appears to be the
major mechanism by which mature lymphocytes
maintain homeostasis. This study aims to ana-
lyse whether different types of haemodialysis
(HD) therapies (low and high flux dialysers) could
modify peripheral blood lymphocyte activation
status and apoptosis death.
Methods: Forty-six stable chronic HD pa-
tients were enrolled in this clinical study (me-
dian age 60.6±17.4 years-old). They were ran-
domly split into three groups – Group 1 (n=20)
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dialyzed with cellulose derivated low-flux dialy-
sers (KUF<10ml/h/mmHg); Group 2 (n=10)
dialyzed with polysulfone (PS) low flux dialysers
(KUF<10ml/h/mmHg); Group 3 (n=16) dialyzed
with PS high-flux dialysers (KUF>20ml/h/
mmHg). There was a control group of 30 healthy
subjects (61.6±19.8 years-old).
Peripheral blood specimens were collected
before and after a dialysis session and the fol-
lowing variables were analysed: membrane
IL2–R (CD25) and HLA-DR T-lymphocyte ex-
pression; lymphocyte dipeptyldipeptidase
(CD26), Fas and FasL expression; lymphocyte
expression of a cytoplasmic membrane
apoptosis marker (flipping of the phosphati-
dylserine residues on cell surface/Annexin
V-FITC assay); IL1β, TNFα, IL2 cytokines plas-
mic concentrations and plasmic enzymatic ac-
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tivity of caspase-1. Methods used for this experi-
ment were flow cytometry and enzyme-linked
immunoassay. Circulating mononuclear cells
lymphocyte enriched were also cultured for 36
hours in vitro and supernatants analysed to
measure IL1β, TNFα, IL2 cytokines concentra-
tions and enzymatic activity of caspase-1.
Results: Lymphocytes of HD patients pre-
sented higher HLA-DR expression and Annexin
V affinity than the control group (HLA-DR:
11.6±7%, Annexin V: 32.2 ± 20.5% versus
8.2±5% and 19.4±9.5%; p<0.001, p<0.01 res-
pectively). After a dialysis session there was a
significant reduction of Annexin V and Fas labeled
lymphocytes in the high flux group (Annexin V:
preHD: 34.5±21.3%; postHD: 25.6±17.3%,
p=0.02; Fas: preHD: 57.3±8.3%; postHD:
52.7±7.1%, p=0.001). This was associated with
a significant increase of CD25 and CD26 ex-
pression in peripheral blood T lymphocytes and
higher IL1β mononuclear supernatant concen-
trations.
Conclusions: We concluded that HD pa-
tients presented increased lymphocyte
apoptosis compared to a normal population with
the same age. Lymphocyte apoptosis was im-
proved by high flux haemodialysis with PS dia-
lysers. A more significant improvement of
apoptotic lymphocyte death after high-flux HD
compared to low flux HD coupled with an eleva-
tion of pro-inflammatory mediators such as IL1β
suggest that this treatment may counteract im-
mune cell death by continuous generation of cell
survival factors and/or removal of high molecu-
lar weight pro-apoptotic factors (“death factors”).
Keywords: Lymphocytes; apoptosis; haemodi-
alysis; high-flux.
INTRODUCTION
Lymphocytes are the main cells of the im-
mune system. They are committed to specific
or adaptive immunity but they also play a main
role in innate immunity, as proved recently1. Key
links between these two main systems could be
presenting dendritic cells, natural killer cells, γδ
T cells. The identification of T cells as a media-
tor of early antigen–independent tissue injury
demonstrates the extensive functional capacity
of lymphocytes beyond adaptive immunity. At the
periphery, outside thymus and bone-marrow,
lymphocytes can suffer essentially three types
of cellular death: programmed cellular death (ge-
netically determined and related to the cell
lifespan: 5 to 7 weeks for naïve lymphocytes, 20
to 30 years for memory cells); apoptotic cell
death (“death-by-instruction” or “death-by-ne-
glect”) and finally, necrotic cell death when there
are sudden or acute modifications of biological
conditions, life non-compatible. In a stable state,
the balance between the withdrawal of positive
signals, that is, signals needed for continued
survival, and the receipt of negative signals would
determine apoptotic lymphocyte death2. Impor-
tant positive extrinsic signals for lymphocyte via-
bility are cytokines such as IL2 and IL7 and low-
affinity MHC interactions. Clearance of these
proinflammatory signals can bring cells to
apoptosis death (death-by-neglect”). Negative
signals (“death-by-instruction”) consist of acti-
vation of death activators (such as TNF-α, Fas
ligand (FasL)) which bind to respective receptors
(TNF receptor, Fas) at the cell surface or simply
threaten cell viability by accumulation of dange-
rous reactive oxygen species3.
End-stage renal patients (ESRD) suffer from
cellular immunodeficiency that can be linked in
part to modifications of lymphocyte apoptosis,
as some recent studies4-7  have suggested. En-
hanced lymphocyte apoptosis can also cause
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immunodeficiency through cell loss and this
parameter (lymphopenia) has been described
as a determinant of survival in those patients8,9.
High-flux haemodialysis is characterized by
back-filtration of dialysis solution in the distal part
of the filter which contributes to what we could
call “obligatory interne haemodiafiltration” (median
of 1.5 to 1.8 litres per hour during a high flux dialy-
sis session). This is accompanied by an increase
in proinflammatory mediators and also cell sur-
vival factors such as interleukin 1 (IL1) due to
mononuclear activation. This process is naturally
dependant on the endotoxin and bacterial con-
tamination of the dialysate and is not totally pre-
vented by the adsorptive dialysis membranes
properties10,11. In addition, high-flux haemodialy-
sis contributes by the same mechanism (inter-
nal filtration) to the removal of bigger molecules
such as proapoptotic factors, which are not com-
pletely known, such as polyamines, advanced
glycosylation end-products (AGEs) and some
hypoproliferative citokines such as IL1012,13.
These two mechanisms, generation of proin-
flammatory signals associated with haemodialy-
sis and improved clearance of middle molecules
by large pore membranes and internal filtration,
could have some impact on lymphocyte survival
in haemodialysis patients and, consequently, on
the immunological state of ESRD patients. This
study aimed to evaluate peripheral blood
lymphocyte apoptosis parameters during low and
high-flux haemodialysis. Our primary objective
was to conclude if dialyser permeability has a
definite influence on these parameters.
PATIENTS AND METHODS
Assay Principle / Study patients
We aimed at analysing whether different
types of haemodialysis (HD) therapies (low and
high flux, cellulose-derivated and synthetic mem-
branes), could modify peripheral blood lympho-
cyte activation status and apoptosis death.
Forty-six stable chronic HD patients were
enrolled in this clinical study. They were randomly
split into three groups (patients of Group 1,
n=20, median age 69±11.8 years-old were
dialyzed with cellulose derivated low-flux dialy-
sers (KUF<10ml/h/mmHg) / 9 patients dialyzed
with cuprophan and 11 patients dialyzed with
hemophan membranes; patients of Group 2,
n=10, median age 48.5±16.3 years-old were
dialyzed with polysulfone (PS) low flux dialysers
(KUF<10ml/h/mmHg); patients of Group 3,
n=16, median age 57.8±18.6 years-old were
dialyzed with PS high-flux dialysers (KUF>20ml/
h/mmHg). There was a control group of 30
healthy subjects, median age 61.6±19.8 years-
old. Table I shows haemodialysis and dialysers’
characteristics.
Peripheral-blood lymphocytes /
Supernatants of in vitro peripheral
mononuclear cells (PMC) cultures
In the study, patients’ peripheral blood speci-
mens were drawn before and after a dialysis
session (average length 210 minutes) and the
following variables were analysed: lymphocyte
subpopulations including Tγδ lymphocytes;
membrane IL2–R (CD25) and HLA-DR T-
lymphocyte expression; lymphocyte dipeptyl-
dipeptidase (CD26), Fas (CD95) and FasL
(CD95L) expression; lymphocyte expression of
a cytoplasmic membrane apoptosis marker (flip-
ping of the phosphatidylserine residues on cell
surface / Annexin V-FITC assay); IL1β, TNFα
and IL2 citokines plasmic concentrations and
enzymatic activity of  caspase 1. Methods used
for this experiment were flow cytometry and en-
zyme-linked immunoassay. Circulating mononu-
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clear cells lymphocyte enriched were also cul-
tured for 36 hours in vitro and supernatants ana-
lysed to measure IL1β, TNFα, IL2 and enzymatic
activity of caspase 1 concentrations.
Blood specimens of the control group were
collected and lymphocytes and mononuclear
cells analysed by the same methods.
Our study used the flow cytometric detection
of FITC-conjugated Annexin V on the surface of
lymphocytes plus supravital exposure to
propidium iodide. The phospholipid phospha-
tidylserine, which is normally hidden within the
plasma membrane, is exposed on the surface
on apoptotic cells early on this process. Annexin
V as a phospholipid–binding protein helped us
to identify the phosphatidylserine residues. The
combination of Annexin V assay with supravital
propidium iodide staining allowed the simulta-
neous detection of living, apoptotic and necrotic
cells (Figs.1, 2).
Mononuclear cells were isolated by centrifu-
gation in Ficoll-Lymphoprep (density gradient
selective for lymphocytes). Cellular preparations
obtained by this method at a concentration of 2
to 5 x105/ml were then incubated with fluorescein-
conjugated Annexin-V and propidium iodide and
analysed by flow cytometry.
Cellular preparations obtained by centrifuga-
tion on Ficoll–Lymphoprep at concentrations of
106/ml were incubated in an oven at 37º, at an
atmosphere with 5% CO2 during 36 hours (RPMI
as culture medium). After incubation mononu-
clear cells were picked up and supernatants
analysed to measure IL1β, TNFα and IL2
cytokines and enzymatic activity of caspase 1.
Statistical analysis
All presented values are mean (m)±standard
deviation(SD). Comparisons between mean
values from the same group of patients, before
and after haemodialysis, were assessed using
a paired t-test. For comparison of mean values
between two different groups we used one-way
analysis of variance with a Student’s t-test (in-
dependent samples t-test or two-sample t-test).
Statistical significance levels were fixed at α 5%
(p<0.05).
RESULTS
Peripheral-blood T lymphocytes
(Haemodialysis patients and Control
group)
The results of this study show that T lympho-
cytes of haemodialysis patients presented higher
HLA-DR, CD26, CD95γδ, CD95CD95L expres-
sion than control group (Table II, IV and V). In-
creased T lymphocyte expression of HLA-DR
and CD26 markers in ESRD patients illustrates
immune system alteration as a chronic and non-
Fig. 1 – Fluorescence microscopy of lymphocytes staining with
Annexin-FITC and propidium iodide (PI).
a,b and c: apoptotic lymphocytes with membrane fixed by
Annexin V-FITC (green fluorescence light);
d: necrotic lymphocyte with double staining: Annexin-FITC and
propidium iodide (PI) (orange fluorescence light).
a                                                 b
c                                                 d
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specific state of lymphocyte activation. CD25 T
lymphocyte expression did not differ between HD
patients and the control group (Table III). Com-
pared to the control group, peripheral blood T
lymphocytes from haemodialysed patients show
a trend towards increased Fas (CD95) and FasL
(CD95L) receptors expression. This difference
did not reach statistical significance except for
the Tγδ lymphocyte sub-population (Table V).
Peripheral blood lymphocytes from hae-
modialysed patients presented increased
Annexin V affinity or phosphatidylserine-binding
protein levels, which indicates increased in vivo
apoptotic rates (Fig. 3).
Evaluations pre and post haemodialysis
(Overall population, Groups 1, 2 and 3)
Expression of CD25 and CD26 receptors
(early expression markers in lymphocyte acti-
vation: CD25 is the α chain of IL2 receptor and
CD26 suit to an exopeptidase that stimulate Th1
lymphocytes to produce cytokines such as INF-γ
and IL2) increased significantly overall imme-
diately after a dialysis session, regardless of the
dialysis membrane composition. On the other
hand, the lymphocyte membrane HLA-DR
receptor expression levels did not change si-
gnificantly after dialysis in the overall population
(Table VI).
T-lymphocyte membrane expression of
CD25 and CD26 receptors increased significantly
immediately after a dialysis session in the group
of patients undergoing high-flux haemodialysis
(Group 3) (Table VII). This was precisely the
same group of patients that presented signifi-
cantly decreased Fas, FasL and Annexin V pe-
ripheral blood lymphocyte expression after a
dialysis session (Table VII and Fig. 4).
Overall, the population studied shows a
marked decrease in the plasma enzymatic ac-
tivity of caspase-1 after one dialysis session
(preHD: 645.4±319; post HD 529.3±340,
p=0.03). Plasma concentrations of IL1β, TNFα
and IL2 cytokines were not significantly different
after a dialysis session for overall population and
for each group (Table VIII).
Fig. 2 –  Flow cytometry image of lymphocytes incubated with fluorescein conjugated
Annexin V and propidium iodide. Percentages of apoptotic (red and yelow colors) and
necrotic cells (green color).
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Measurement of in vitro peripheral-blood
mononuclear cell IL1β, TNFα and IL2 cytokines
levels suggest that dialyzed patients produce and
secrete significantly more cytokines than indi-
viduals from the control group (supernatant
IL1β: haemodialysis patients (n=46) preHD
238±191.1 pg/ml, control group (n=30)
105±214.8 pg/ml, p=0.03; supernatant TNFα:
haemodialysis patients (n=46) preHD 75±72.8
pg/ml, control group (n=30), 25± 39 pg/ml,
p=0.003; supernatant IL2: haemodialysis pa-
tients (n=46) preHD 8±5.7 pg/ml, control group
(n=30) 2.8±1.6 pg/ml, p=0.0001). Furthermore,
compared to the control group, the enzymatic
activity of caspase 1 in peripheral-blood mono-
nuclear cell cultures in dialyzed patients was
increased (supernatant activity of caspase 1:
haemodialysis patients (n=46) preHD 7.6±5 pg/
ml, control group (n=30) 2.6±3 pg/ml, p=0.001)
(Table IX).
After a single dialysis session, there was a
significant decrease of IL1β concentrations in
peripheral-blood mononuclear cells superna-
tants obtained from low-flux membrane haemo-
dialyzed patients (Group 1 and Group 2, n=30 -
supernatant IL1β preHD 155.1±151.3 pg/ml,
postHD 65.5±52.8 pg/ml, p=0.04). No IL1β
supernatant concentration alterations were ob-
served for patients undergoing high-flux mem-
branes dialysis (Group 3) (Table IX).
DISCUSSION
(ESRD) patients present different abnormali-
ties of the immune system that are not totally
corrected by haemodialysis treatments6,14-16.
This particular condition of immunodeficiency of
ESRD patients is characterized by functional
modifications of elements of innate immunity
such as polymorphonuclear17-20, macrophage21-24
and NK cells25-27. The essential actors of spe-
Fig. 3 – Lymphocyte expression of Annexin V (haemodialysis patients and control group)
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cific immunity, lymphocytes, are also functionally
vulnerable in uraemia as demonstrated by the
modifications in humoral and cellular immunity
that have been exhaustively studied over the last
15 years. A short overview of some important
studies into immunological abnormalities of clas-
sical adaptative response associated with urae-
mia is presented in Tables X and XI.
In recent years, apoptosis has been reported
as a major pathway by which mature lym-
phocytes maintain homeostasis3,28. Lymphocyte
cellular death regulation is a form of immune
system modulation and our understanding of this
mechanism could help to explain certain immu-
TABLE I
Haemodialysis and dialyzers’ characteristics
Type of dialysis
membrane/Flux
Cuprophan/
low-flux
Hemophan/
low-flux
Polysulfone/
low-flux
Polysulfone/
high-flux
Dialysis solution
(composition/
bacteriologic quality)
Bicarbonate standard 3
mEq/L of Ca2+ / <0.1
UFC/ml and  LAL<0.025
U/ml
Bicarbonate standard 3
mEq/L of Ca2+ / <0.1
UFC/ml e  LAL<0.025
U/ml
Bicarbonate standard 3
mEq/L de Ca2+ / <0.1
UFC/ml e  LAL<0.025
U/ml
Bicarbonate
standard 3 mEq/L de
Ca2+ / <0.1 UFC/ml e
LAL<0.025 U/ml
Qd (Dialysis solution flux,
ml/m)
500 500 500 800
Qb (blood flux, ml/m) 250-350 250-350 250-350 400-500
Anticoagulation Discontinuous:
heparine 50U/Kg at
beginning and
1000U/hour,
(stopping at last hour)
Discontinuous:
heparine 50U/Kg at
beginning and
1000U/hour,
(stopping at last hour)
Discontinuous:
heparine 50U/Kg at
beginning and
1000U/hour,
(stopping at last hour)
Discontinuous:
heparine 50U/Kg at
beginning and
1000U/hour,
(stopping at last hour)
Ultrafiltration (UF)
control/rate of UF per hour,
ml/h
Volumetric/
200-1000
Volumetric/
200-1000
Volumetric/
200-1000
Volumetric/
200-1000
Dialyzer model/dialysis
membrane polymer
Alwall GFE-12, Gambro/
Cuprophan
Lundia Aria 700,
Gambro/
Hemophan
F6 HPS, Fresenius/
Polysulfone
Hemoflow HF 60L,
Fresenius/
Polysulfone
KUF (ml/h/mmHg) 6.0 8.5 8.5 33
Area (m2) 1.3 1.3 1.3 1.3
KoA urea (ml/m)ª/
Ko urea/m2(ml/m)ª/
Kurea Qb 300ml/m, UF=0ª
545 / 419 / 221 730 / 561 /244 581/ 447 / 237 615 / 473 / 253
Kcreat. (ml/m)
(Qb 200ml/m,
Qd 500 ml/m)ª
151 170 167 172
Priming volume 65 120 82 82
Residence time (Priming
volume/Qb 350ml/m)
0.18 0.34 0.24 0.23
(Membrane thickness (µm)
/Fiber diameter (µm)
8 / 200 6.5 / Plate dialyzer 40 / 200 40 / 200
Sterilization Ethylene oxide Ethylene oxide Steam Ethylene oxide
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CD26 (dipeptyldipeptidase)
HD
patients
(n=46)
Control
group
(n=30)
Significance
of
differences
CD26 (%)
 
45.9±10,6 39.8±9.46 p=0.006ª
CD26CD3 (%) 40.9±10,5 3.,3±9,3 n.s. ª
CD26CD4 (%) 32.1±9.2 3.,3±9,3 n.s. ª
CD26CD8 (%) 9.51±4.21 7.52±3.81 p=0.02ª
CD26CD3CD25 (%) 15.6±6.03 16.5±5.79 n.s. ª
nological abnormalities such as immunodeficien-
cies and autoimmune diseases.
There are experiments that suggest that
lymphocyte apoptosis is disrupted in ESRD pa-
tients and this fact could contribute to the cellu-
lar immunodeficiency of these patients4-6,8,29-32.
Our study aimed at concluding if there are dif-
ferences in lymphocyte apoptosis death para-
meters after haemodialysis with dialysers of dif-
ferent water permeability (low and high flux,
derivatized cellulose and synthetic membranes).
As mentioned before, lymphocyte death could
present apoptotic characteristics due to activa-
tion of the normal genetic programme of cellular
survival or to a process of activation-induced cell
death (AICD), called “death-by-instruction” or
“death-by-neglect”3. On the other hand, there is
the process of necrotic lymphocyte death due
to acute aggressions, not life compatible. Du-
ring haemodialysis treatments, the aggression
or pre-lethal stimulus that lymphocytes could
suffer would induce apoptosis death and not
necrosis, as these cells resist extreme condi-
tions of cellular hypoxia (ATP synthesis in these
cells is based on glycolysis). In addition, removal
of uremic apoptotic molecules or instead ge-
neration of cell survival factors could contribute
to a decrease of lymphocytes apoptosis mar-
kers after a haemodialysis session10-13. The
question could be raised whether the final ba-
lance between pro and anti apoptotic stimulus
contributes or not, to the cellular immunodefi-
cient state observed in end stage renal patients
treated by haemodialysis. We also might be sure
if the differences between high and low flux
modalities impact on lymphocyte death.
The results of our study showed that haemo-
dialysis patients presented a slight lymphope-
nia but no significant differences in lymphocyte
subpopulations compared with a normal popu-
lation of the same age (results not showed).
There was no difference in the IL2 receptor
TABLE II
HLA-DR lymphocyte expression in hemodialysis patients and
control group
 a two-sample t-test
TABLE III
CD25 lymphocyte expression in haemodialysis patients and
control group
a two-sample t-test.
a two-sample t-test
TABLE IV
CD26 (dipeptyldipeptidase) lymphocyte expression in HD
patients and controls
CD3/DR
(%)
Significance
of differences
Haemodialysis patients (n=46) 11.6±7.2
Control group (n=30) 8.2±5 p=0.009ª
CD25/CD3
(%)
Significance
of differences
Haemodialysis patients (n=46) 18±6.1
Control group (n=30) 20.8±6.4 n.s.ª
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CD95 (Fas)
HD patients
 (n=41)
Control
group
(n=30)
Significance
 
CD95 (%) (n=41) 56.2±9.81 51.7±13.1 n.s.ª
CD95CD3 (%) (n=41) 46.5 ±9.4 45.6±11.75 n.s.ª
CD95 γδ (%) (n=32) 2.9±1.8 2.1±1.57 p=0.04ª
CD95 L (FasL)
CD95L (%) (n=12) 2±1.9 1.4±1.86 n.s.ª
CD95LCD3 (%) (n=12) 1.46 ±1.92 0.57±0.59 n.s.ª
CD95LCD95(%) (n=12) 1.81±2.52 0.49±0.58 p=0.049ª
cur totally independently of antigen1. Chemokines
such as RANTES and oxygen free radicals are
some products that could be playing an impor-
tant role in this process of non-specific T cell
activation1,34. In ESRD these products accumu-
late and could contribute to the up-regulation of
pro-inflammatory genes on lymphocytes and to
this state of cell pre-activation that compromises
adequate immune response12,13. Impaired
lymphocyte calcium metabolism in end-stage
renal disease could also contribute to the pre-
sence of some activation signals in those pa-
tients. Enhanced calcium intracellular influx and
sustained elevation of intracellular calcium acts
as an important trigger for nucleus transcriptional
activation of cytokine genes such as the IL2
gene35,36.
TABLE V
CD95 (Fas) and CD95L (FasL) lymphocyte expression in HD
patients and controls
a two-sample t-test
TABLE VI
 % of peripheral blood lymphocytes CD25, HLA-DR, CD26,
CD95 and CD95L positive (pre and post haemodialysis
session).
(CD25) peripheral blood lymphocyte expression
in haemodialysis patients compared with the
control group but there was a sustained increase
in HLA-DR expression in peripheral T-lym-
phocytes (CD3 receptor positive). Compared to
the control group, CD26 lymphocyte expression
was increased in haemodialysis patients, par-
ticularly in cytotoxic lymphocytes (CD8 positive).
CD26, a membrane associated peptidase
(dipeptidyl-peptidase IV), is characterized by
costimulatory properties of activation of lympho-
cytes. The importance of signalling via CD26 has
been proved by researchers into specific inhibi-
tors that suppress T cell proliferation in vitro,
particularly Th1 lymphocytes33.  Our observa-
tions confirm previous findings that describe a
state of lymphocyte preactivation in uraemia that
persists even after the beginning of regular
haemodialysis14,30. The knowledge of molecular
mechanisms of lymphocyte activation had al-
lowed to conclude that T cell activation can oc-
a paired t test
Overall Group (n=46)
Before
HD
After
HD
CD25 (%)
(n=46)
21.4±7                    24.2±8
p<0.001a
HLADR (%)
(n=46)
22.3±10               21.9±10
n.s. a
CD26 (%)
(n=46)
45.9±11             49.7±11
p<0.001 a
CD95 (%)
(n=41)
56.2±10             53.7±9
p=0.01 a
CD95L (%)
(n=12)
2±1.9            2.9±2.3
p=0.02 a
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TABLE VII
 % of peripheral blood T lymphocytes CD25, CD26, CD95 and CD95L positive
(pre and post haemodialysis session).
apaired t-test.
Fig. 4 – Peripheral blood lymphocytes Annexin V positive (pre and post haemodialysis session)
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In our study we observed that haemodialysis
treatments, independent of the dialyser mem-
brane composition, cellulose-based or synthetic
such as polysulfone, maintained and increased
the immune cell activation state. We observed
increased expression of CD25 and CD26
lymphocyte activation markers after a dialysis
session (CD25 - 21.4±7% before HD; 24.2±8%
after HD, p<0.001; CD26 - 45.9±11% before HD;
49.7±11% after HD, p<0.001) (Table VI). The
apaired t-test.
TABLE VIII
Plasmic concentrations of IL1β, TNFα and IL2 cytokines and enzymatic activity of caspase 1.
TABLE IX
Supernatant concentrations of IL1β, TNFα and IL2 cytokines and enzymatic activity of caspase 1.
Supernatant IL1β
(pg/ml)
Supernatant TNFα
(pg/ml)
Supernatant IL2
(pg/ml)
Supernatant
activity of caspase 1
(pg/ml)
Control group
(n=30)
105±214.8 25±39 2.8±1.6 2.6±3
Before HD
238±191.1
After HD
180.5±213
Before HD
75±72.8
After HD
85.4±118
Before HD
8±5.7
After HD
9±8
Before HD
7.6±5
After HD
8.6±6.4
Haemodialysis
patients (n=46)
an.s., p=0.07 an.s., p=0.22 p=0.13 an.s., p=0.2
Before HD
179±177.4
After HD
75.7±56
Before HD
66.3±33.6
After HD
93.4±52.7
Before HD
16.2±5.5
After HD
15.1±4.2
Before HD
9.1±8
After HD
3.4±8
Group 1
(n=20)
an.s., p=0.10 an.s., p=0.16 an.s., p=0.35 an.s., p=0.23
Before HD
172.5±147
After HD
23.1±26.5
Before HD
72±35.4
After HD
54.5±51.4
Before HD
10.3±7.3
After HD
12.1±6.7
Before HD
4±3.1
After HD
3.4±4.2
Group 2
(n=10)
an.s., p=0.04 an.s., p=0.27 an.s., p=0.34 an.s., p=0.2
Before HD
269±198
After HD
259±232
Before HD
76.6±93.4
After HD
99±153.1
Before HD
5.5±4.3
After HD
6.9±5.2
Before HD
7.1±4.7
After HD
8.8±6.2
Group 3
(n=16)
an.s., p=0.44 an.s., p=0.17 an.s., p=0.2 an.s., p=0.22
Plasmic IL1β
(pg/ml)
Plasmic TNFα
(pg/ml)
Plasmic IL2
(pg/ml)
Plasmic activity of caspase
1
(pg/ml)
Before HD
17.6±65.4
After HD
3.5±4.3
Before HD
9.7±7.1
After HD
11.8±4.8
Before HD
6.2±5.2
After HD
6.1±5.6
Before HD
645.4±319
After HD
529.3±340
Haemodialysis
patients (n=46)
an.s., p=0.11 an.s., p=0.14 an.s., p=0.49 ap=0.03.
Before HD
5±9
After HD
1.3±1.5
Before HD
7±4.6
After HD
9.2±4
Before HD
10.4±6.2
After HD
11±6
Before HD
535±326.7
After HD
495±306.4
Group 1 (n=20)
an.s., p=0.16 an.s., p=0.16 an.s., p=0.42 an.s., p=0.1
Before HD
2.7±3.1
After HD
4.3±3.2
Before HD
10±12.6
After HD
11.3±6
Before HD
3±1.1
After HD
2.8±1.5
Before HD
523±322
After HD
322±237
Group 2 (n=10)
an.s., p=0.21 an.s., p=0.43 an.s., p=0.39 an.s., p=0.27
Before HD
7.8±12.8
After HD
3.5±5.4
Before HD
9±4.5
After HD
10.5±5
Before HD
8.3±6.1
After HD
8±6.5
Before HD
691±318
After HD
543.3±365
Group 3 (n=16)
an.s., p=0.11. an.s., p=.031 an.s., p=0.48 an.s., p=0.15
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lymphocyte membrane HLA-DR receptor
lymphocyte expression levels do not change sig-
nificantly after dialysis in the overall population.
This difference might be explained by the diffe-
rent categories of genes, CD25 and CD26 being
early genes, expressed within 1-2 hours after
stimulation and HLA-DR gene being a late gene,
expressed more than 2 days after cellular acti-
vation37. The number of studies that demons-
trated an increase of lymphocyte expression of
IL2 receptor (α chain or CD25 protein) in ESRD
patients after a haemodialysis session and on
the steady state19,38-41 is smaller than those that
showed an increase in the same soluble receptor
(soluble CD25)42-52. Only a few studies report
no difference in IL2R membrane expression on
lymphocytes after haemodialysis 53,54. Probably
this is an effect of the transitory cellular expres-
Modification
* Lymphocytopenia
* Cellular immunodeficiency  (LT)
- Increase of  membranous  and soluble receptor IL2R
- Decrease of in vitro lymphocyte proliferative response
- Decrease of lymphocitotoxicity
* Deficit of TRC/CD3 Lymphocyte T CD4 expression
* Increase of CD4 and CD8 soluble receptors
concentrations
* Rise of in vitro IL1b mononuclear production
* Increase of plasmic concentration of IL1R and IL1R
antagonist
* Increase of in vitro  mononuclear apoptosis
* Decrease of  lymphocyte Bcl2 concentration; increase
of plasmic Bcl2 concentration
Reference
Hoy WE et al, 1978
Bansal KO et al, 1979
Wakabayaashi Y et al, 1989
Gogo KO et al, 1998
Fernandez-Fresnedo G et al, 2000
Beaurain G et al, 1989
Schachowski J et al, 1991
Caruana RJ et al, 1992
Descamps-Latscha B et al, 1995
Schachowski J et al, 1991
Puppo F et al, 1991, Lauricella AM et al, 1991,
Donati D et al, 1992, Kaul H et al, 2000
Lang I et al, 1982
Schachowski J et al, 1991
Matsumoto Y et al, 1998
Pereira BJ et al, 1992
Higuchi T et al, 1997
Pereira BJ et al, 1992 e 1994
Descamps-Latscha B et al, 1995
Higuchi T et al, 1997
Matsumoto Y et al, 1995 e 1997
Heidenreich S et al, 1996
Martin Malo A et al, 2000
Fernandez-Fresnedo G et al, 2000
Buemi M et al, 1998
Fernandez-Fresnedo G et al, 2000
TABLE X
Abnormalities of specific immunity in pre-terminal uraemia.
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TABLE XI
Abnormalities of specific immunity in ESRD patients.
Modification
* Lymphocytopenia (LB, LT CD8)
* Increase of CD4 and CD8 soluble receptors
concentrations
* Increase of soluble CD23 receptor
* Cellular immunodeficiency  (LT)
- Decrease of T lymphocyte IL2 production
- Increase of membrane and soluble IL2R
- Decrease of in vitro lymphocyte proliferative
response
* Increase of  CD3/HLA-DR  T lymphocyte %
* Decrease of TCRαβ receptor on T lymphocytes
* Deficit of antigen presenting cells (APC)
* Th2 polarization of T cells
*
Decrease of lymphocyte intracellular pH (deficit of
Na+/K+ pump)
* Increase of  calcium lymphocyte intracellular
concentration
* Increase of  IL1, IL6 and TNFα production
Reference
Hoy WE WT et al, 1878 and 1981; Ramirez G et al, 1988
Tchorzewski H et al, 1989; Hory B et al, 1991
Baj Z et al, 1992; Ueki Y et al, 1993
Rabb H et al, 1994; Deenitchina SS et al, 1995; Gogo KO
et al, 1998
Matsumoto Y et al, 1998
Descamps-Latscha B et al, 1993
Chatenoud L et al, 1986; Raskova J et al, 1986
Beaurain G et al, 1989; Revillard JP et al, 1990
Gerez L et al, 1991
Chatenoud L et al, 1986, Beaurain G et al, 1989
Walz G et al, 1990, Zaoui P et al, 1991
Donati D et al, 1991, Vaziri ND et al, 1991
Stefoni S et al, 1991, Caruano RJ et al, 1992
Patarca R et al, 1992; Matsumoto Y et al, 1993
Koziol-Montewka M et al, 1997; Shu KH et al,
1998Daichou Y et al, 1999; Meier P et al, 2000
Gast GC et al, 1977; Morita Y et al, 1997
Alevy YG et al, 1984; Raskova et al, 1986; Zaoui P et al,
1991
Cheng QL et al, 1991; Stefoni S et al, 1991
Matsumoto Y et al, 1993;  Ueki Y et al, 1993
Deenitchina SS et al, 1995 
Stefoni S et al, 1991; Deenitchina SS et al, 1995 
Mirapeix E et al, 1985;  Girndt M et al, 1993 e 2001
Daichou Y et al, 1999; Sester U et al, 2000; Girndt M et
al, 2001
Rombola G et al, 1995
Alexiewicz JM et al, 1990 and 1996
Luger A et al, 1987 ; Paydas S et al, 1991;Donati D et al,
1991; Memoli B et al, 1991; Mege JL et al, 1991; Dinarello
CA, 1992; Patarca R et al, 1992; Haubitz M et al,
1992Dinarello CA et al, 1995; Lonnemann G et al, 1995;
Sá H et al, 1996; Descamps-Latscha B et al, 1996; Donati D
et al, 1997; Higuchi T et al, 1997; Morita Y et al, 1997;
Kaizu Y et al, 1998; Kimmel PL et al, 1998; Roccatello D et
al 1998; Rostaing L et al 2000.
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sion of CD25 that is rapidly secreted to blood
circulation. The data presented in this study on
the CD26 receptor, an exopeptidase that stimu-
lates Th1 lymphocytes to produce cytokines
such as INF-γ and IL2 and participates in
transendothelial lymphocyte migration, led us to
conclude that the increase of its expression af-
ter haemodialysis, could contribute to the per-
petuation of the inflammatory state associated
to uraemia and to dysregulation of the normal
distribution of blood and tissue lymphocytes33.
Increased production of IL1β by ESRD mono-
nuclear cultures enriched on lymphocytes in
comparison with the control group strengthens
the idea of pre-activation of these kinds of
leukocytes in uraemia even when patients are
undergoing haemodialysis.
High flux haemodialysis treatment resulted in
higher peripheral mononuclear activation than
low flux haemodialysis in our study. After a dia-
lysis session, peripheral blood mononuclear cells
of patients dialyzed with low-lux membranes
(cellulose based and polysulfone dialysers) pre-
sented a significant decrease in IL1β production
and secretion onto in vitro cultures. The patients
dialyzed with high flux membranes presented no
difference in IL1β supernatant concentrations
after the dialysis session (Table IX). We con-
cluded that patients dialyzed with high flux dia-
lysers maintained an elevated rhythm of produc-
tion and secretion of the pro-inflammatory IL1β
cytokine. The stimulus to this increased produc-
tion and extra-cellular secretion of IL1β might be
the diffusive and convective transport of bacte-
rial products across the membrane. These pro-
cesses are more important when the ultrafiltra-
tion per hour is lower than two litres per hour
and backdiffusion and backfiltration are
strengthed55. The difference in supernatants
PBMC cultures IL1β concentrations data be-
tween low and high flux haemodialysis patients
can also be explained by different distribution of
this cytokine between the intra and the extracel-
lular compartiments. As demonstrated by
Lonnemann G et al, when patients currently
dialyzed with cuprophan membranes change to
high flux synthetic membranes, the total in vitro
IL1β mononuclear production is identical but the
percentage of secretion of this cytokine to the
extracellular medium increases56.
Heidenreich S et al and Jaber BL et al proved
that, paradoxically, the increase of pro-inflamma-
tory cytokines such as TNFα or IL1 could tempo-
rally inhibit the apoptotic cascat6,57. In agreement
with these results we also found a significantly
decrease of Fas, FasL and Annexin V peripheral
blood lymphocyte expression in the same group
that presented significantly higher supernatant
PBMC cultures IL1β concentrations after a dialy-
sis session: the high flux polysulfone group. This
important observation suggests that, after a
haemodialysis session with polysulfone high flux
dialysers, peripheral lymphocytes presented a
significant improvement of susceptibility to
apoptosis death (reduction of Fas lymphocyte
expression: preHD: 47.4±10%, postHD: 43.7±9%,
p=0.009) and of effective apoptosis rate (de-
crease of annexin V expression: preHD:
34.5±21.3%, postHD: 25.6±17.3%, p=0.02). It is
important to mention that the dialyser membrane
didn’t seem to be as important as water permea-
bility as the Group 2 patients, who were dialyzed
with polysulfone low-flux dialysers, didn’t show
significant variation of lymphocyte Fas expression
or Annexin V expression.
Our data confirm that haemodialysis appa-
rently didn’t seem to have influence on plasmic
cytokine concentrations such as IL1β, TNFα or
IL2, independent of the water permeability of the
dialyser used. The same results were described
by Rostaing L et al in a similar study with diffe-
rent methods24.
Overall, our results demonstrated that
apoptosis lymphocytes markers decrease after
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a dialysis session in the global population stu-
died and this was more evident and significant
in the group undergoing high flux haemodialy-
sis. Heidenreich S et al described, as we do, a
decrease in the percentage of peripheral mono-
nuclear cells presenting apoptotic morphology
after a dialysis session as compared to the be-
ginning but did not observe differences between
groups of patients dialyzed with cuprophan or
polysulfone or high and low flux haemodialysis57.
Other researchers presented data suggesting
that quality of dialysis membrane could have
some influence on apoptotic leukocyte markers.
Carracedo et al, Martin Malo et al and
Rosenkranz et al reported an increase of in vitro
apoptosis rate if leukocytes were incubated with
cuprophan membranes as compared to
polysulfone or polyacrilonitril synthetic mem-
branes58-60. Jaber et al observed a decrease of
in vitro polymorphonuclear apoptosis after incu-
bation of these cells with plasma of patients
dialyzed with cuprophan. It was not verified if ins-
tead of cuprophan, patients were dialyzed with
cellulose acetate or polysulfone membranes61.
Recently, Soriano S et al conducted a clinical
study similar to ours, and concluded that
lymphocyte apoptosis in uraemia is influenced
by the permeability of the dialysis membrane.
They described a decrease in lymphocyte
apoptosis in patients dialyzed with high-flux
polysulfone membranes as compared to low flux
hemophan or low-flux polysulfone62.
The observation in our study of a decrease in
lymphocyte Fas expression after a dialysis ses-
sion in the overall population and the fact that
this reduction was more accentuated in the group
of patients undergoing high-flux polysulfone
haemodialysis running in tandem with a decrease
in Annexin V expression suggest that the dialytic
treatment in general, and the high flux modality
in particular, contributes to the elimination of cells
such as lymphocytes with apoptotic characte-
ristics.  The behaviour of plasmic enzymatic ac-
tivity of caspase 1 proves this. In the overall
population studied, plasma enzymatic activity of
caspase 1 decreased significantly after dialysis
(preHD: 645.4±319; post HD 529.3±340,
p=0.03). Experimental studies based on gene
deletion demonstrated a major role played by
caspase 1 (“interleukin-1β-converting enzyme or
ICE) in apoptosis induced by receptor Fas. Most
of the caspases are intracellular but active
caspase 1 is localized on the cellular mem-
brane63. The decrease of the percentage of
lymphocytes with Fas expression after high flux
haemodialysis associated to the decrease of
Annexin V staining could be related to the elimi-
nation of cells from peripheral circulation by the
mechanism of activation induced cell death (due
to the presence of signals promoting cell sur-
vival such as pro-inflammatory cytokines as IL1)
or to removal of proapoptotic factors of large
molecular weight. In addition, high-flux haemo-
dialysis contributes to the removal of bigger
molecules such as proapoptotic factors not com-
pletely known such as polyamines, advanced
glycosylation end-products (AGEs) and some
hypoproliferative citokines such as IL1012,13. It is
not plausible that a cell which exhibits Annexin V
staining could return to the primitive stage, as at
that point there is no reversibility of apoptotic
cascade and death is definitive.
Compared to a control group, peripheral blood
mononuclear cells of dialysis patients cultured
in vitro without stimulus synthetized and secreted
significantly more IL1β, TNFα and IL2 cytokines.
Peripheral blood mononuclear supernatants of
dialysis patients also presented higher
enzymatic activity of caspase 1 when compared
to a control group. These observations ratify the
in vivo results: mononuclear cells of end stage
renal patients undergo accelerated apoptosis
occurring in tandem with a state of cellular acti-
vation.
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According to our present data, and compared
to a normal population, we can affirm that hae-
modialysis patients show a immune dysre-
gulation that is characterized by a chronic and
non-specific state of lymphocyte and monocyte
activation (HLA-DR and CD26 exopeptidase in-
creased cellular expression, increased sponta-
neous secretion of pro-inflammatory cytokines
such as IL1β, TNFα and of IL2 lymphokine) and
an increased expression of apoptosis lympho-
cytes markers (Fas/Fas ligand system, mem-
brane annexin-V binding properties). Both cellu-
lose and polysulfone based haemodialysis
maintained and stimulated the immune cell ac-
tivation status (increased expression of CD25
and CD26 lymphocyte activation markers after
a single dialysis session independent of the dia-
lysis membrane). Peripheral mononuclear cell
activation rate was higher in high-flux haemodia-
lysis than in low-flux haemodialysis.
In conclusion, a significant improvement of
lymphocyte apoptosis rate was observed after
a single dialysis session in patients undergoing
high-flux haemodialysis with polysulfone dialy-
sers as compared to low-flux haemodialysis with
cellulose derivated and polysulfone dialysers.
This observation was associated to a significant
elevation of pro-inflammatory mediators such as
IL1β in high-flux group, indicating that this treat-
ment may counteract immune cell death by con-
tinuous generation of cell survival factors or by
better removal of pro-apoptotic factors (“death
factors”).
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